HomeBiotech

Biotech

Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

September 28, 2023

Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis

Nevisense detects skin barrier dysfunction in children with Atopic Dermatitis

September 28, 2023

Cytovance Biologics Announces Dr. Axel Schleyer to Expand Footprint and Service Offering as Chief Commercial Officer

Cytovance Biologics Announces Dr. Axel Schleyer to Expand Footprint and Service Offering as Chief Commercial Officer

September 27, 2023

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer

September 27, 2023

Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field

Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field

September 27, 2023

Nayo Biotechnology Showcases Cutting-Edge Automation Solutions at ARABLAB LIVE 2023 in Dubai

Nayo Biotechnology Showcases Cutting-Edge Automation Solutions at ARABLAB LIVE 2023 in Dubai

September 27, 2023

Remegen’s Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

Remegen’s Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

September 27, 2023

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations

September 26, 2023

Global Next Generation Sequencing (NGS) Informatics Research Analysis Report 2023-2030: DNASTAR, Fabric Genomics, Partek, and DNAnexus Drive NGS Informatics Innovations

Global Next Generation Sequencing (NGS) Informatics Research Analysis Report 2023-2030: DNASTAR, Fabric Genomics, Partek, and DNAnexus Drive NGS Informatics Innovations

September 26, 2023

Infectious Disease Research Through Unmet Needs Analysis, Pipeline Assessment, Disease Intelligence, Pricing Strategies, and Market Access Analysis by Disease Landscape Insights

Infectious Disease Research Through Unmet Needs Analysis, Pipeline Assessment, Disease Intelligence, Pricing Strategies, and Market Access Analysis by Disease Landscape Insights

September 26, 2023

« 1 … 36 37 38 39 40 … 82 »